Experts in multiple myeloma weigh the benefits and risks of second malignancies following CAR-T in Multiple Myeloma – Cancer Network

Rahul Banerjee shared a post by Cancer Network on X, adding:

“Thanks Cancer Network,  The American Society for Transplantation and Cellular Therapy, and double thanks to our expert Noopur Raje for speaking with me about risk of second malignancies following CAR-T in MMsm. Lots we’re learning about this topic, mainly from our lymphoma colleagues… but some myeloma-specific nuances as well.”

Quoting Cancer Network:

“Experts in multiple myeloma weigh the benefits and risks of administering CAR T-cell therapy to patients based on prior reports of secondary malignancies.”

Additional information

Source: Rahul Banerjee/X and Cancer Network/X

Rahul Banerjee is an assistant professor at Fred Hutchinson Cancer Center at the University of Washington. He completed his residency from the University of Pennsylvania health system. He completed his fellowship in haematology and oncology from University of California, San Francisco. He has authored over 70-peer reviewed publications. His clinical interests include multiple myeloma.